Followers | 28 |
Posts | 4474 |
Boards Moderated | 1 |
Alias Born | 09/22/2006 |
Thursday, February 14, 2019 9:32:23 AM
-------------------------------
Vice President, Corporate Development
POSITION SUMMARY:
The Vice President, Oncology Business Development will report to the CEO and, in partnership with the Executive Team, will define and execute Halozyme’s plan to build a multi-product oncology company. S/he will drive the company’s growth strategy through the identification, evaluation, execution, and integration of compelling acquisition and investment opportunities complementary to our two pillar business.
ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:
These may include but are not limited to:
Develop a vision for a Halozyme oncology portfolio that will excite and engage investors
Lead execution of diligence, detailed assessment and valuation of oncology companies and assets identified as potentially attractive for Halozyme to access
Lead and execute the end-to-end M&A process, including identification of key value drivers during diligence, creation, and execution of the integration plan and monitoring and reporting of and business objectives
Recommend approach and terms for acquisition/licensing of new assets
Lead process for evaluation, selection and negotiation with regional partners
Develop valuation model for potential regional partnerships opportunities
Establish internal process for rapid search and evaluation for identification of new asset opportunities and newly emerging competitive threats and as we build our portfolio
Cultivate robust network with banks, companies, and opinion leaders to facilitate deal identification and consummation
Manage reporting of asset’s long-term value, operational achievements, risks, and dependencies; proactively identify potential planning gaps, suggest mitigation's to open issues/risks and drive resolutions
Create integration processes/playbooks that incorporate prior experience and industry best practices across the cross-functional team
ADDITIONAL FUNCTIONS AND RESPONSIBILITIES:
Identify new ENHANZE opportunities and new platform technologies and communicate these to ENHANZE Business Development team
Other duties as assigned
EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES:
A minimum of a Bachelor’s degree with at least 15 years’ business development experience within the biopharmaceutical industry (and equivalent combination of education and experience may be considered)
Demonstrated track record of success leading a range of transactions including company or asset acquisition, out-licensing assets and mergers and acquisitions
Proven experience playing major role on transactions in pharma/biotech
Previous experience as an investor or working within Private Equity Group assessing and making recommendations on acquisitions of companies or assets
Former scientific and commercialization expertise in oncology
Expert level skills building deal models
Deep knowledge of US and EU markets; Asia Pac experience, a plus
MS, PhD, MD, CFA or MBA preferred
TECHNICAL KNOWLEDGE REQUIRED:
Equipment: PC, scanners, facsimile machine, voice mail and e-mail systems, and common office machines, or ability to be trained.
Software Knowledge : Windows, MS Office (Outlook, Word, Excel, PowerPoint, Visio)
INTERNAL AND EXTERNAL RELATIONSHIPS:
Develop internal and external relationships that successfully drive business objectives
Collaborate with cross-functional teams consisting of functional experts and target company leaders throughout the M&A process
EFFORT REQUIRED/ENVIRONMENTAL CONDITIONS:
Physical Activities : On a continuous basis, sit at desk for a long period of time; intermittently answer telephone and write or use a keyboard to communicate through written means. Some walking and lifting up to 20 lbs. may be required. The noise level in the work environment is usually low to moderate. The physical demands described above are representative of those that must be met by an employee to successfully perform the essential functions and responsibilities of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions and responsibilities.
Laboratory Activities, if applicable: Biology and chemical laboratory environments experience needed. Environmental health and safety requirements also apply.
TRAVEL:
Travel may be required up to 50% of your time
The more you know, the less you don't know.
Recent HALO News
- ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • InvestorsHub NewsWire • 10/10/2024 12:09:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 09:39:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/09/2024 08:09:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/08/2024 08:08:02 PM
- Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE® • PR Newswire (US) • 10/03/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/26/2024 10:06:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/26/2024 08:05:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/25/2024 08:00:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/24/2024 08:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM